# US 2023/0304913 A1 · Flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0304913 A1
- Document ID: US20230304913A1
- Status: Published application
- Kind: A1
- Application number: 18/181,803
- Filed: 2023-03-10
- Published: 2023-09-28
- Earliest claimed: 2015-10-09
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Victor R. Cairns; Jose Ignacio Sancho Chavida; Christine DeMaria
- Web page: https://patentgrep.com/patent/US20230304913A1

## CPC

- G01N 15/14: Optical investigation techniques, e.g. flow cytometry
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C12N 15/85: for animal cells
- G01N 33/5044: {involving specific cell types}
- C07K 2317/10: characterized by their source of isolation or production
- C12N 2510/02: Cells for production
- G01N 15/149: specially adapted for sorting particles, e.g. by their size or optical properties
- G01N 2333/70592: CD52
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS). In some aspects, the disclosure provides a drug-selection-free method for batch production of producer cells using FACS. Such batch production methods and compositions can be further utilized to generate clonal populations of producer cells, e.g., for large-scale manufacturing of a polypeptide of interest.

## Claims

### Claim 1

A method of fluorescence activated cell sorting (FACS) to batch select producer cells expressing a target polypeptide, the method comprising:
(a) providing a heterogeneous population of producer cells, wherein the producer cells in the population express varying levels of a FACS selectable polypeptide and a target polypeptide that are encoded by the same multicistronic mRNA,
(b) selecting from the heterogeneous population of producer cells a first heterogeneous sub-population of producer cells using FACS, wherein the producer cells in the first heterogeneous sub-population express the FACS selectable polypeptide at a level that is higher than the level of at least 80% of the producer cells in the heterogeneous population in (a), and
(c) expanding the first heterogeneous sub-population of producer cells in drug-selection-free medium, thereby producing an expanded first heterogeneous sub-population of producer cells.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
(d) selecting from the expanded first heterogeneous sub-population of producer cells in (c) a second heterogeneous sub-population of producer cells using FACS, wherein the producer cells in the second sub-population express the FACS selectable polypeptide at a level that is higher than the level of at least 80% of the producer cells in the expanded first heterogeneous sub-population of producer cells in (c), and
(e) expanding the second heterogeneous sub-population of producer cells in a drug-selection-free medium, thereby producing an expanded second heterogeneous sub-population of producer cells.

### Claim 3 (depends on 1)

The method of claim 1, further comprising isolating the target polypeptide from the expanded first or second heterogeneous sub-population.

### Claim 4 (depends on 1)

The method of claim 1, further comprising isolating one or more single producer cells from the expanded first or second heterogeneous sub-population and individually culturing the one or more single producer cells to produce clonal populations of the one or more single producer cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the expanded first heterogeneous sub-population of producer cells yields a 1.2- to 5-fold improvement in production of the target polypeptide compared to that of the heterogeneous population of producer cells in (a).

### Claim 6 (depends on 1)

The method of claim 1, wherein the expanded second heterogeneous sub-population of producer cells yields a 1.2- to 2.5-fold improvement in production of the target polypeptide compared to that of the expanded first heterogeneous sub-population of producer cells in (c).

### Claim 7 (depends on 4)

The method of claim 4, wherein at least one of the clonal populations of the one or more single cells yields a 5- to 30-fold improvement in production of the target polypeptide compared to that of the heterogeneous population of producer cells in (a).

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the drug-selection-free medium is methotrexate-free medium or methionine sulphoximine-free medium.

### Claim 13 (depends on 1)

The method of claim 1, wherein the heterogeneous population of producer cells in (a) is produced by transfecting cells with a vector that encodes the multicistronic mRNA and subjecting the transfected cells to one round of medium-based selection to select cells expressing varying levels of the multicistronic mRNA.

### Claim 14 (depends on 13)

The method of claim 13, wherein the vector further contains a dihydrofolate reductase (DHFR) gene.

### Claim 15 (depends on 14)

The method of claim 14, wherein the medium-based selection is methotrexate-containing medium or nucleotide-deficient medium.

### Claim 16 (depends on 1)

The method of claim 1, wherein the heterogeneous population of producer cells in (a) is produced by transfecting cells with a vector that encodes the multicistronic mRNA and subjecting the transfected cells to FACS to select cells expressing varying levels of the multicistronic mRNA.

### Claim 17 (depends on 1)

The method of claim 1, wherein the multicistronic mRNA comprises a first open reading frame (ORF) that encodes the FACS selectable polypeptide and a second ORF that encodes the target polypeptide, wherein the first ORF is 5′ to the second ORF.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first ORF has a non-AUG start codon.

### Claim 19 (depends on 18)

The method of claim 18, wherein the second ORF has an AUG start codon.

### Claim 20

(canceled)

### Claim 21 (depends on 17)

The method of claim 17, wherein the ORF that encodes the FACS selectable polypeptide is devoid of any AUG sequences.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the target polypeptide is selected from the group consisting of therapeutic agents, secreted proteins, antibodies, and Fc fusion proteins.

### Claim at position 21

24-26. (canceled)

### Claim 27 (depends on 1)

A clonal population of producer cells that express a FACS selectable polypeptide and a target polypeptide obtainable by the method of claim 1.

### Claim 28

(canceled)

### Claim 29

A method of increasing viability of cells after fluorescence activated cell sorting (FACS), the method comprising:
using a first round of FACS to select based on a viability marker a first sub-population of cells from a population of cells expressing a target polypeptide, and
using a second round of FACS to select based on the viability marker a second sub-population of cells from the first sub-population of cells,
wherein the first round and second round of FACS occur within 8 hours of each other.

### Claim at position 25

30-45. (canceled)
